US 12,065,489 B2
Claudin-6 antibodies and drug conjugates
Dylan Conklin, Los Angeles, CA (US); Martina S. McDermott, Los Angeles, CA (US); Neil A. O'Brien, Los Angeles, CA (US); Michael J. Palazzolo, Los Angeles, CA (US); Dennis Slamon, Los Angeles, CA (US); Erika Von Euw, Los Angeles, CA (US); and Peter Bowers, Los Angeles, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jun. 22, 2022, as Appl. No. 17/846,900.
Application 17/846,900 is a continuation of application No. 17/441,157, abandoned, previously published as PCT/US2020/023981, filed on Mar. 20, 2020.
Claims priority of provisional application 62/821,391, filed on Mar. 20, 2019.
Prior Publication US 2023/0049752 A1, Feb. 16, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/28 (2013.01) [A61K 47/65 (2017.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); G01N 33/5748 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2319/00 (2013.01)] 59 Claims
 
1. An antigen-binding protein that binds to a human Claudin6 (CLDN6) protein (SEQ ID NO: 200) and comprises
(i) HC CDR1 comprising GFTFSNYW (SEQ ID NO: 23),
(ii) HC CDR2 comprising IRLKSDNYAT (SEQ ID NO: 24),
(iii) HC CDR3 comprising NDGPPSGX (SEQ ID NO: 457), wherein X at position 8 is selected from the group consisting of S, T, A, C, and Y;
(iv) LC CDR1 comprising ENIYSY (SEQ ID NO: 20),
(v) LC CDR2 comprising NAK (SEQ ID NO: 21), and
(vi) LC CDR3 comprising QHHYTVPWT (SEQ ID NO: 22).